Scientific scope and capacities.
Biomarker discovery and precision diagnostics represent a cornerstone of EATRIS-CZ. The platform spans genomics, transcriptomics, epigenomics, proteomics and metabolomics—including single-cell and spatial approaches—together with advanced analytics and clinically anchored translation. Services support patient stratification, discovery of diagnostic/prognostic/predictive markers, and stepwise analytical validation with pathways for rapid transfer into clinical diagnostics where appropriate (including work in accredited environments).
Main services to users (examples).
- Study design support for biomarker pipelines (discovery → verification → validation → clinical implementation planning);
- Multi-omics data generation (sample processing, omics measurements, QC and harmonised metadata capture);
- Targeted verification/quantification (e.g., MS-based targeted workflows) and assay optimisation;
- Integrated interpretation and patient stratification through secure clinical–omics integration workflows;
- Support for national and European reuse through FAIR-aligned data curation and OMOP harmonisation pipelines.
Technology basis strengthened in 2020–2024.
IMTM implemented high-capacity sequencing (NovaSeq 6000 and a high-throughput genetic analyser) and expanded MS-based profiling (Ascend MS, high-sensitivity MS, Triple Quad 6500+ and automated SPE-MS/MS workflows), improving throughput, sensitivity and reproducibility and shortening the time from discovery signals to validation-ready biomarker evidence.
In the era of personalized medicine, biomarkers play a crucial role in diagnostic and treatment decisions. Biomarkers also represent a key strategy for innovative clinical trials (e.g. patient stratification) that will facilitate cost-effective and speedy assessment of new drugs for efficacy and marketing approval. EATRIS Biomarkers Product Platform facilitates the validation and development of biomarkers for the prevention, diagnosis and prognostic assessment of disease as well as for the prediction of therapy response. EATRIS biomarker institutions utilize cutting edge infrastructures as well as a range of scientific, technological, clinical and regulatory expertise to operate professional and high-quality standardized services in biomarker development.
EATRIS-CZ participation
- IMTM, CEITEC-MU, 1.FM CU
Major technologies/infrastructures
- PCR techniques, NGS, DNA hybridization and sequencing, flow cytometry, imaging, specialized cell culture and modification techniques, cell and molecules purification techniques, proteomics, genomics, metabolomics, mass spectrometry